FDA Grants Rare Pediatric Disease Designation to BPGbio’s Investigational Treatment for Epidermolysis Bullosa
The U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation for BPGbio, Inc.’s BPM31510T, an investigational treatment for epidermolysis bullosa (EB). BPM31510T targets cellular and mitochondrial processes that promote wound healing. BPM31510T has completed a phase 1 trial for EB and phase 2 for SCC. The FDA’s Rare Pediatric Disease Designation is intended for companies developing […]